CYBN
CybinCYBN
CYBN
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
18% more funds holding
Funds holding: 45 [Q3] → 53 (+8) [Q4]
1.75% less ownership
Funds ownership: 36.34% [Q3] → 34.6% (-1.75%) [Q4]
6% less capital invested
Capital invested by funds: $64.6M [Q3] → $61M (-$3.56M) [Q4]
86% less call options, than puts
Call options by funds: $1.87M | Put options by funds: $13.1M
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$35
421%
upside
Avg. target
$86
1,180%
upside
High target
$150
2,132%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Eddie Hickman 50% 1-year accuracy 4 / 8 met price target | 421%upside $35 | Buy Initiated | 13 Mar 2025 |
HC Wainwright & Co. Patrick Trucchio 25% 1-year accuracy 46 / 181 met price target | 2,132%upside $150 | Buy Maintained | 13 Feb 2025 |
Canaccord Genuity Sumant Kulkarni 28% 1-year accuracy 9 / 32 met price target | 986%upside $73 | Buy Maintained | 12 Feb 2025 |
Financial journalist opinion
Negative
Zacks Investment Research
3 weeks ago
Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Cybin Inc. (CYBN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet
The consensus price target hints at a 988.7% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Business Wire
1 month ago
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its third quarter ended December 31, 2024, and recent business highlights. “As we advance our lead clinical programs, CYB003 and CYB004, our focus in 2025 remains on continued.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 952.2% in Cybin Inc. (CYBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
Business Wire
2 months ago
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the launch of its first strategic partnership agreement (“SPA”) with Segal Trials in furtherance of Cybin's multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of Major De.
Neutral
Business Wire
2 months ago
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to provide a year-end summary of its key accomplishments in 2024 and upcoming milestones for 2025. “In 2024, we made significant progress toward our goal of transforming the mental health treatment landscape,” said Dou.
Neutral
Business Wire
2 months ago
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the Lytham Partners 2025 Investor Healthcare Summit taking place virtually on January 13, 2025. The fireside chat.
Neutral
Business Wire
3 months ago
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the presentation of two posters at the American College of Neuropsychopharmacology (“ACNP”) Annual Meeting taking place December 8-11, 2024, in Phoenix, Arizona. The data presented include 12-month efficacy result.
Neutral
Business Wire
3 months ago
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, and Amir Inamdar, MBBS, DNB (Psych), FFPM, Cybin's Chief Medical Officer, will participate in the Water Tower Research Fireside Chat Series taking place.
Neutral
Business Wire
4 months ago
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced unprecedented 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin program in development for the potential adjunctive treatment of major depressive disorder (“MDD”). As previ.
Charts implemented using Lightweight Charts™